Eli Lilly and Company is acquiring biotech firm AtaiBeckley for an up-front payment of $2.8 billion to integrate the psychedelic drug candidate BPL-003 into its neuroscience portfolio. According to company terms, Lilly will pay $6.75 per outstanding share, with potential milestone payments reaching an additional $1 billion ($2.50 per share), according to the deal terms. … Read more
The Department of Veterans Affairs (VA) and the Department of Health and Human Services (HHS) signed a memorandum of understanding (MOU) on Monday to coordinate research into psychedelic drugs for treating veterans’ mental health disorders. This agreement aims to expand clinical trial participation, train medical staff for potential administration of approved psychedelic medications, and collect … Read more
A recent clinical report involving an octogenarian with advanced Alzheimer’s disease has sparked new scientific debate regarding latent cognitive function. After consuming psilocybin-containing mushrooms, the patient experienced a temporary but significant recovery of speech, memory, and motor skills. Researchers emphasize that this single-patient observation, while compelling, does not constitute a cure for dementia and carries … Read more